Telix posts Q1 2026 commercial and operational update

Telix Pharmaceuticals has posted its Q1 2026 commercial and operational update, reporting US$230 million in unaudited group revenue and reaffirming its full-year outlook.

The company said quarterly revenue was up 24% year over year and 11% quarter over quarter. Precision Medicine revenue came in at US$186 million, also up from the prior year and prior quarter.

Telix reaffirmed FY 2026 revenue guidance of US$950 million to US$970 million. The company said the quarter reflected continued commercial momentum across its portfolio.

On the pipeline side, Telix said Part 1 of the ProstACT Global study met safety and dosimetry objectives without new safety signals. The company also said it resubmitted the TLX101-Px NDA to the U.S. FDA and filed a European marketing authorization application. In addition, Telix said the TLX591-Px NDA was accepted in China by the NMPA.

The update appeared first in the market on April 6 and was later filed with the SEC on April 7. It is the latest sign that Telix is pairing revenue growth with progress on multiple regulatory fronts.

No change to the company’s stated guidance was announced in the update.